Print this page
cellular therapy
-
A 5-year Longitudinal Observational Study of the Natural History and Management of Patients with Hepatocellular Carcinoma
Protocol: 001720Applicable Disease Sites: Liver
-
Open-Label Dose-Finding and Dose-Expansion Study to Evaluate the Safety, Expansion, Persistence, and Clinical Activity of UCART20x22 (in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin s Lymphoma (B-NHL).
Protocol: 012208Principal Investigator:
- Matthew Matasar
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
Phase 1/Expansion Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory Lymphoma.
Protocol: 012312Principal Investigator:
- Joanna Rhodes
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Phase 1 Open-Label, Multi-Center Study of the Safety, Pharmacokinetics (PK), and Anti-tumor Activity of LYT-200 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), or with Relapsed/Refractory, High/Very High Risk Myelodysplastic Syndrome (MDS).
Protocol: 022204Principal Investigator:
- Dale Schaar
Applicable Disease Sites: Myeloid and Monocytic Leukemia
Other Hematopoietic -
A Phase 1/1b Open-label, Multicenter Clinical Study of MK-0472 as Monotherapy and Combination Therapy in Participants with Advanced/Metastatic Solid Tumors.
Protocol: 052410Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase II Trial of Tislelizumab Consolidation after Liver-Directed Therapy for Hepatocellular Carcinoma.
Protocol: 072105Principal Investigator:
- Salma Jabbour
Applicable Disease Sites: Liver -
A Phase II, Open-Label, Multi-Cohort, Multicenter Study in Patients with Unresectable Heptocellular Carcinoma and CHILDPUGH B7 and B8 Cirrhosis.
Protocol: 072309Principal Investigator:
- Howard Hochster
Applicable Disease Sites: Liver -
Phase II Single-Arm Study of Durvalumab and Bevacizumab Following Transarterial Radioembolization Using Yttrium-90 Glass Microspheres (TheraSphere ) in Unresectable Hepatocellular Carcinoma Amenable to Locoregional Therapy.
Protocol: 072311Principal Investigator:
- Sharon Li
Applicable Disease Sites: Liver -
A Phase III, Randomised, Open-label, Sponsor-blinded, Multicentre Study of
Rilvegostomig in Combination with Bevacizumab with or without Tremelimumab
as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Protocol: 072502Principal Investigator:
- Stacey Stein
Applicable Disease Sites: Liver -
Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator's Choice in HLAA*02:01-Positive Participants with Previously Treated Advanced Melanoma.
Protocol: 092203Principal Investigator:
- Sarah Weiss
Applicable Disease Sites: Melanoma, Skin -
A Phase 1b Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO).
Protocol: 092305Principal Investigator:
- Sarah Weiss
Applicable Disease Sites: Melanoma, Skin -
Expanded Access Protocol: Umbilical Cord Blood Infusions for Children with Brain Injuries
Protocol: 112207Principal Investigator:
- Archana Sharma
Applicable Disease Sites: Any Site -
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-Oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma.
Protocol: 112305Principal Investigator:
- Richard A Drachtman
Applicable Disease Sites: Hodgkin's Lymphoma -
Collection of Peripheral Blood Mononuclear Cells (PBMCs) from Healthy Subjects.
Protocol: 192001Principal Investigator:
- Christian Hinrichs
Applicable Disease Sites: Any Site -
Screening Protocol for Clinical Trial Eligibility.
Protocol: 192101Principal Investigator:
- Christian Hinrichs
Applicable Disease Sites: Any Site